MAGEA3 and non-small cell lung carcinoma: In a previous retrospective study, a GS composed of 84 immune-related genes associated with clinical benefits of the recombinant melanoma-associated antigen (MAGE)-A3 combined with AS15 immunostimulant (recMAGE-A3+ AS15, further referred to as MAGE-A3 immunotherapeutic) was identified in patients with malignant metastatic melanoma or adjuvant non-small cell lung cancer (NSCLC).13